Fujitsu taps generative AI to help speed drug development
TOKYO -- Fujitsu has teamed up with the government-backed Riken research institute to develop generative AI technology that predicts the state of a drug's target protein in the body more than 10 times as fast as existing methods.
Using images of proteins taken with advanced cryo-electron microscopy, Fujitsu and Riken have applied generative artificial intelligence to reproduce the proteins as three-dimensional structures in motion.